James Tarala, MD
Family Medicine · East Syracuse, NYNPI 1588819734
Payments from drug & device makers
Across 85 payments — averaging $17.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$302
- Astellas Pharma US Inc$259
- Johnson & Johnson$168
- Amgen$79
- GSK$76
- Amarin Pharma, Inc.$71
- plus $575 from 18 others
What the payments were for
- Food & beverage$1,41893%
- Education$1127%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 20 | $302 |
| Astellas Pharma US Inc | 10 | $259 |
| Johnson & Johnson | 4 | $168 |
| Amgen | 5 | $79 |
| GSK | 5 | $76 |
| Amarin Pharma, Inc. | 5 | $71 |
| Biohaven Pharmaceuticals, Inc. | 4 | $62 |
| Teva Pharmaceuticals USA, Inc. | 4 | $54 |
| Pfizer | 4 | $53 |
| Boehringer Ingelheim | 3 | $48 |
| Novo Nordisk | 3 | $43 |
| Lilly USA, LLC | 3 | $42 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $40 |
| Boston Scientific | 1 | $35 |
| AstraZeneca | 2 | $33 |
| Merck | 2 | $25 |
| Jazz Pharmaceuticals Inc. | 1 | $23 |
| Abbott | 1 | $22 |
| Axonics, Inc. | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| IBSA Pharma Inc. | 1 | $15 |
| Corcept Therapeutics | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$101
How this compares
$1,529 in reported general payments places this provider in the 70th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 78 | $109,865 |
| JardianceEmpagliflozin | 84 | $102,793 |
| TrulicityDulaglutide | 81 | $91,507 |
| RybelsusSemaglutide | 60 | $84,863 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 97 | $78,615 |
| MounjaroTirzepatide | 55 | $71,087 |
| EliquisApixaban | 70 | $70,238 |
| FarxigaDapagliflozin Propanediol | 49 | $60,940 |
| Wellbutrin XlBupropion Hcl | 22 | $48,428 |
| ProliaDenosumab | 20 | $34,338 |
| XareltoRivaroxaban | 20 | $33,320 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 17 | $25,133 |
| WegovySemaglutide | 15 | $23,302 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 13 | $20,483 |
| LinzessLinaclotide | 14 | $18,353 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Wegovy | $43 | $218,029153 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $42 | $162,594136 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Stiolto Respimat | $48 | $132,496112 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $76 | $87,651110 claims |
| PfizerEliquis | $53 | $70,23870 claims |
| AstraZenecaFarxiga, Symbicort | $33 | $66,28863 claims |
| AmgenProlia | $79 | $34,33820 claims |
| Johnson & JohnsonXarelto | $168 | $33,32020 claims |
| MerckJanumet Xr | $25 | $25,13317 claims |
| AbbVieLinzess | $302 | $18,35314 claims |
| Astellas Pharma US IncMyrbetriq | $259 | $11,05320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,321 family medicine providers in New York.
Other family medicine in East Syracuse
- Louis BonavitaEast Syracuse$674K
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
- Richard RuhOrchard Park$769K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.